Seasonal Allergic Rhinitis Therapeutics

1. Alvesco patent expiration

Treatment: Method of treating inflammatory conditions; Maintenance treatment of asthma as prophylactic therapy in adult and adolescent patients 12 years of age and older. patent claims method for treating a resp...

ALVESCO's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5775321 COVIS Seal configuration for aerosol canister
Jul, 2015

(10 years ago)

US5683677 COVIS Medicinal aerosol formulations
Nov, 2014

(11 years ago)

US5605674 COVIS Medicinal aerosol formulations
Feb, 2014

(11 years ago)

US6036942 COVIS Seal configuration for aerosol canister
Apr, 2013

(12 years ago)

US5482934 COVIS Pregna-1,4-diene3,20-dione-16-17-acetal-21 esters, process for their preparation, composition, and methods for the treatment of inflammatory conditions
Oct, 2017

(8 years ago)

US6264923 COVIS Medicinal aerosol formulation of ciclesonide and related compounds
May, 2018

(7 years ago)

US6006745 COVIS Device for delivering an aerosol
Dec, 2016

(9 years ago)

US6120752 COVIS Medicinal aerosol products containing formulations of ciclesonide and related steroids
May, 2018

(7 years ago)

US8371292 COVIS Use of ciclesonide for the treatment of respiratory diseases
Feb, 2028

(2 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Oct 20, 2011
M(M-125) Dec 17, 2015

Drugs and Companies using CICLESONIDE ingredient

NCE-1 date: 20 October, 2010

Market Authorisation Date: 10 January, 2008

Dosage: AEROSOL, METERED

More Information on Dosage

ALVESCO family patents

Family Patents

2. Clarinex patent expiration

Treatment: Treatment of chronic idiopathic urticaria; A method of treating nasal and non-nasal symptoms of seasonal allergic rhinitis; Treatment of all...

CLARINEX IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6100274

(Pediatric)

ORGANON 8-chloro-6,11-dihydro-11- ](4-piperidylidine)-5H-benzo[5,6]cyclohepta[1,2-bpyridine oral compositions
Jan, 2020

(6 years ago)

US7214684

(Pediatric)

ORGANON Methods for the treatment of allergic rhinitis
Jun, 2015

(10 years ago)

US5607697

(Pediatric)

ORGANON Taste masking microparticles for oral dosage forms
Dec, 2015

(10 years ago)

US7211582 ORGANON Methods for treating urticaria using descarboethoxyloratadine
Dec, 2014

(11 years ago)

US7618649 ORGANON Extended release oral dosage composition
Dec, 2020

(5 years ago)

US7214684 ORGANON Methods for the treatment of allergic rhinitis
Dec, 2014

(11 years ago)

US7214683 ORGANON Compositions of descarboethoxyloratadine
Dec, 2014

(11 years ago)

US5607697 ORGANON Taste masking microparticles for oral dosage forms
Jun, 2015

(10 years ago)

US6100274 ORGANON 8-chloro-6,11-dihydro-11- ](4-piperidylidine)-5H-benzo[5,6]cyclohepta[1,2-bpyridine oral compositions
Jul, 2019

(6 years ago)

US7214683

(Pediatric)

ORGANON Compositions of descarboethoxyloratadine
Jun, 2015

(10 years ago)

US7211582

(Pediatric)

ORGANON Methods for treating urticaria using descarboethoxyloratadine
Jun, 2015

(10 years ago)

US7618649

(Pediatric)

ORGANON Extended release oral dosage composition
Jun, 2021

(4 years ago)

US7405223

(Pediatric)

ORGANON Treating allergic and inflammatory conditions
Jan, 2020

(6 years ago)

US7405223 ORGANON Treating allergic and inflammatory conditions
Jul, 2019

(6 years ago)




Drugs and Companies using DESLORATADINE ingredient

Market Authorisation Date: 14 July, 2005

Dosage: TABLET, ORALLY DISINTEGRATING; TABLET

How can I launch a generic of CLARINEX before it's drug patent expiration?
More Information on Dosage

CLARINEX family patents

Family Patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Clarinex patent expiration

Treatment: Treatment of allergic rhinitis; Treatment of chronic idiopathic urticaria

CLARINEX IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6514520 MERCK SHARP DOHME Stabilized antihistamine syrup
Jun, 2018

(7 years ago)

US7214684 MERCK SHARP DOHME Methods for the treatment of allergic rhinitis
Dec, 2014

(11 years ago)

US7214683 MERCK SHARP DOHME Compositions of descarboethoxyloratadine
Dec, 2014

(11 years ago)

US7211582 MERCK SHARP DOHME Methods for treating urticaria using descarboethoxyloratadine
Dec, 2014

(11 years ago)

US7214684

(Pediatric)

MERCK SHARP DOHME Methods for the treatment of allergic rhinitis
Jun, 2015

(10 years ago)

US7214683

(Pediatric)

MERCK SHARP DOHME Compositions of descarboethoxyloratadine
Jun, 2015

(10 years ago)

US7211582

(Pediatric)

MERCK SHARP DOHME Methods for treating urticaria using descarboethoxyloratadine
Jun, 2015

(10 years ago)

US6514520

(Pediatric)

MERCK SHARP DOHME Stabilized antihistamine syrup
Dec, 2018

(7 years ago)




Drugs and Companies using DESLORATADINE ingredient

Market Authorisation Date: 01 September, 2004

Dosage: SOLUTION

How can I launch a generic of CLARINEX before it's drug patent expiration?
More Information on Dosage

CLARINEX family patents

Family Patents